You just read:

Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO

News provided by

Innovent Biologics, Inc.

Sep 20, 2019, 02:28 ET